At the molecular level, these tumor characteristic mutations included PTEN (88%), RPL22 (33%), KRAS (35%), PIK3CA (54%), PIK3R1 (40%), and ARID1A (37%) with high TMB levels (18 × 106 Muts/Mb) and certain TIL [24]. This evidence concerns the gene KRAS and neoplasm.